Exhibit 10.26

[***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

[gjflqkwy2kvs000001.jpg]

395 Pine Tree Road, Suite 310  

Ithaca, New York 14850  

p- 607-254-4698

f. 607-254-5454

www.ctl.cornell.edu

 

October 31, 2018

Jyrki Mattila, PhD

Executive Vice President of Business Development

Recro Pharma, Inc.

490 Lapp Road, Malvern PA 19355

Email: jmattila@recropharma.com

RE:AMENDMENT

to the License Agreement by and between Recro Pharma, Inc. (hereinafter
“LICENSEE”) and Cornell University (“Cornell”), as represented by its Center for
Technology Licensing at Cornell University (hereinafter “CTL”) effective June
30, 2017, and amended effective October 24, 2017 (Cornell Contract
#C2017-12-10946)

Effective as of the date of the last signature below (“Second Amendment Date”),
the undersigned parties agree to hereby modify the License Agreement referenced
above as follows:

1)In Paragraph 3.3 Due Diligence, replace (a)(ii) and (a)(iii) with the
following:

(ii) [***];

(iii)  [***];

2)These changes do not otherwise change the terms and conditions of the
Agreement.

 

 

 

 

--------------------------------------------------------------------------------

 

IN WITNESS THEREOF, the parties have caused this instrument to be executed in
duplicate as of the Amendment Date written above.

 

Cornell University

 

Recro Pharma, Inc.

 

 

 

 

 

 

 

By:

 

/s/ Brian J. Kelly, PhD

 

By:

 

/s/ G. A. Henwood

 

 

 

 

 

 

 

Name:

 

Brian J. Kelly, PhD

 

Name:

 

G.A. Henwood

Title:

 

Director, Technology Licensing

 

Title:

 

CEO & President

 

 

 

 

 

 

 

Date:

 

November 29, 2018

 

Date:

 

November 27, 2018